T. Rowe Price Investment Management, Inc. Verve Therapeutics, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $158 Billion
- Q2 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 4,528,712 shares of VERV stock, worth $22.6 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
4,528,712
Previous 4,576,424
1.04%
Holding current value
$22.6 Million
Previous $60.8 Million
63.63%
% of portfolio
0.01%
Previous 0.04%
Shares
8 transactions
Others Institutions Holding VERV
# of Institutions
174Shares Held
74.8MCall Options Held
115KPut Options Held
144K-
Alphabet Inc. Mountain View, CA12.3MShares$61.7 Million3.79% of portfolio
-
Black Rock Inc. New York, NY6.62MShares$33.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.26MShares$26.3 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.87MShares$19.4 Million0.01% of portfolio
-
State Street Corp Boston, MA3.35MShares$16.7 Million0.0% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $300M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...